1. Home
  2. BCTXZ vs SVC Comparison

BCTXZ vs SVC Comparison

Compare BCTXZ & SVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BCTXZ
  • SVC
  • Stock Information
  • Founded
  • BCTXZ N/A
  • SVC 1995
  • Country
  • BCTXZ Canada
  • SVC United States
  • Employees
  • BCTXZ 12
  • SVC N/A
  • Industry
  • BCTXZ
  • SVC Real Estate Investment Trusts
  • Sector
  • BCTXZ
  • SVC Real Estate
  • Exchange
  • BCTXZ Nasdaq
  • SVC Nasdaq
  • Market Cap
  • BCTXZ N/A
  • SVC N/A
  • IPO Year
  • BCTXZ N/A
  • SVC N/A
  • Fundamental
  • Price
  • BCTXZ $1.10
  • SVC $2.32
  • Analyst Decision
  • BCTXZ
  • SVC Strong Buy
  • Analyst Count
  • BCTXZ 0
  • SVC 2
  • Target Price
  • BCTXZ N/A
  • SVC $6.00
  • AVG Volume (30 Days)
  • BCTXZ N/A
  • SVC 1.7M
  • Earning Date
  • BCTXZ N/A
  • SVC 05-06-2025
  • Dividend Yield
  • BCTXZ N/A
  • SVC 1.72%
  • EPS Growth
  • BCTXZ N/A
  • SVC N/A
  • EPS
  • BCTXZ N/A
  • SVC N/A
  • Revenue
  • BCTXZ N/A
  • SVC $1,895,857,000.00
  • Revenue This Year
  • BCTXZ N/A
  • SVC N/A
  • Revenue Next Year
  • BCTXZ N/A
  • SVC N/A
  • P/E Ratio
  • BCTXZ N/A
  • SVC N/A
  • Revenue Growth
  • BCTXZ N/A
  • SVC 0.80
  • 52 Week Low
  • BCTXZ N/A
  • SVC $1.71
  • 52 Week High
  • BCTXZ N/A
  • SVC $6.34
  • Technical
  • Relative Strength Index (RSI)
  • BCTXZ N/A
  • SVC 60.19
  • Support Level
  • BCTXZ N/A
  • SVC $2.08
  • Resistance Level
  • BCTXZ N/A
  • SVC $2.40
  • Average True Range (ATR)
  • BCTXZ 0.00
  • SVC 0.12
  • MACD
  • BCTXZ 0.00
  • SVC 0.03
  • Stochastic Oscillator
  • BCTXZ 0.00
  • SVC 75.76

About BCTXZ BriaCell Therapeutics Corp. Warrant

BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Share on Social Networks: